BioNTech (NASDAQ:BNTX - Get Free Report) had its price target increased by investment analysts at BMO Capital Markets from $130.00 to $143.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. BMO Capital Markets' target price points to a potential upside of 35.74% from the company's current price.
A number of other research analysts have also commented on BNTX. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. HC Wainwright restated a "buy" rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and raised their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial initiated coverage on BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective for the company. Finally, Berenberg Bank initiated coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $144.03.
View Our Latest Stock Report on BioNTech
BioNTech Stock Down 3.2 %
Shares of NASDAQ BNTX opened at $105.35 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $25.26 billion, a PE ratio of -50.17 and a beta of 0.30. BioNTech has a one year low of $76.53 and a one year high of $131.49. The business's fifty day moving average price is $116.76 and its 200-day moving average price is $113.06.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same period in the prior year, the company posted $1.90 EPS. BioNTech's revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts anticipate that BioNTech will post -3.88 EPS for the current year.
Hedge Funds Weigh In On BioNTech
Several institutional investors and hedge funds have recently bought and sold shares of BNTX. Baillie Gifford & Co. boosted its stake in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC boosted its position in BioNTech by 22.2% during the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after buying an additional 1,401,547 shares during the period. Flossbach Von Storch SE grew its holdings in BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after acquiring an additional 47,236 shares during the last quarter. Capital International Investors grew its holdings in BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after acquiring an additional 394,434 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of BioNTech in the fourth quarter valued at about $69,999,000. 15.52% of the stock is currently owned by institutional investors.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
